Proofs: Industry Updates

A new study by researchers at Columbia University focused on dental equipment screenings for drug misuse, finding 77% of dentists ask patients about illicit drug use and 54% of dentists believe that such screenings should be their responsibility. Results of the study are online in the journal Addiction
Those dentists who embraced substance misuse screening as part of their professional role were more likely to query about misuse with their patients (86%) compared with those who did not accept such screenings as their responsibility (68%). In general, both agreement with the purpose of and use of health history forms with substance misuse questions increased with the amount of prior training and knowledge regarding substance use.
Dentists are the second-largest group of prescribers of opioid pain medication. “Because dental care routinely involves treating pain and emergencies, dentists may encounter substance-seeking patients who complain of pain more severe than anticipated based on the nature of their dental condition, who report lost prescriptions for opioid pain medications, or who only seek dental treatment sporadically,” noted Carrigan Parish, DMD, associate research scientist in the Department of Sociomedical Sciences.-Columbia University Mailman School of Public Health press release 13 August 2015
PeriRx officially launches SaliMark OSCC Test for oral squamous cell carcinoma
PeriRx LLC (Broomall, Pennsylvania), a developer of noninvasive, oral diagnostic technology, has officially launched SaliMark OSCC, a molecular DNA test for the early detection of oral squamous cell carcinoma. The salivary test is now available from the online ordering systems of Henry Schein Dental, Patterson Dental, and Benco Dental.
Development of the noninvasive test was based on NIH-funded research, with initial discovery and prevalidation work conducted by David Wong, DMD, DMSc, of the University of California at Los Angeles. In addition, more than 10 years of research at the National Institute of Dental and Craniofacial Research and National Institute of Health supports SaliMark OSCC as a scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma.
The test is indicated for use when a visual oral examination (via naked eye or fluorescent device) detects a suspicious lesion or oral mucosal abnormality. SaliMark OSCC’s highly accurate risk assessment capabilities can help the clinician make a more informed and confident decision on whether to refer the patient to a specialist for a biopsy.-DentistryIQ 26 August 2015
Dentsply and Sirona enter into definitive merger agreement
Dentsply International Inc. (York, Pennsylvania; NASDAQ: XRAY) and Sirona Dental Systems Inc. (New York City, New York; NASDAQ: SIRO) announced in September 2015 that the boards of directors of both companies unanimously approved a definitive merger agreement. The combination will create a combined company with the largest sales and service infrastructure in the dental supplies industry with 15,000 employees globally.
The combined company will be called Dentsply Sirona and trade on the NASDAQ under the symbol XRAY. The global headquarters will be located in York, Pennsylvania, the location of Dentsply’s current headquarters, while the international headquarters will be located in Salzburg, Austria.
Upon closing of the transaction, Jeffrey T. Slovin, president and CEO of Sirona, will serve as CEO of the combined company and will be a member of the board of directors. Bret W. Wise, chair and CEO of Dentsply, will serve as executive chair of the combined company. The executive chair will work in collaboration with the CEO to execute the corporate strategy and to integrate the companies and cultures. From Dentsply, Christopher T. Clark and James G. Mosch will serve as president and chief operating officer, technologies, and president and chief operating officer, dental and health-care consumables, respectively. From Sirona, Ulrich Michel will serve as executive vice president and chief financial officer. The board of directors will consist of 11 members, six of whom (including Wise) are current Dentsply directors and five of whom (including Slovin) are current Sirona directors.